Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics, 108, E24. presented at the 2001.. (2001).
Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans. J Infec Dis, 197, 580-583. presented at the 02/2008. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18237269. (2008).
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine. N Engl J Med, 354, 1343-1351. presented at the 03/2006. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16571878. (2006).